12Oct 2021
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase 2 multicentre, open‐label feasibility trial

Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase 2 multicentre, open‐label feasibility trial

Pemphigus vulgaris and pemphigus foliaceus are potentially life‐threatening autoimmune disorders triggered by immunoglobulin G (IgG) autoantibodies against mucosal and epidermal desmogleins. There is an unmet need for fast‐acting drugs that enable patients to achieve early sustained remission with reduced corticosteroid reliance. To investigate efgartigimod, an engineered Fc fragment that inhibits the activity of the neonatal Fc receptor, thereby reducing serum IgG levels, for treating pemphigus...

  • #dermatology

Like

Save

Share